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PGC-1Orphan nuclear receptors, in a manner comparable to classic steroid hormone receptors, regulate key
developmental and physiological processes. However, the lack of appropriate pharmacological tools has often
hindered the identiﬁcation and study of their biological functions. In this review, we demonstrate that
functional and physiological genomics are effective alternatives to discover biological functions associated
with orphan nuclear receptors. Indeed, we document that these approaches have allowed for the
unambiguous identiﬁcation of the estrogen-related receptors (ERRs) α, β, and γ (NR3B1, 2, and 3) as global
regulators of cellular energy metabolism. We further show that although the three ERR isoforms control
analogous gene networks, each isoform performs unique biological functions in a tissue-speciﬁc manner in
response to a variety of physiological stressors. Finally, we discuss how the activity of the three ERR isoforms
contributes to the development and progression of metabolic diseases as well as to the adaptation of cancer
cells to their unique bioenergetic requirement. This article is part of a Special Issue entitled: Translating
nuclear receptors from health to disease.slating nuclear receptors from
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As transcription factors, nuclear receptors mediate their biological
activities through the transcriptional regulation of speciﬁc genes.
Therefore, the identiﬁcation of gene regulatory networks controlled
by nuclear receptors is critical to understand the roles of these
proteins in development, normal physiology, and diverse pathologies,
including metabolic diseases and hormone-dependent cancers.
During the last decade, the sequencing of mammalian genomes
and the subsequent introduction of high-throughput approaches
aimed at the analysis of transcription factor/genome interactions and
modulation of transcriptomes have led to the development of the ﬁeld
of functional genomics. In particular, the application of chromatin
immunoprecipitation (ChIP)-based technologies along with gene
expression analyses has uncovered novel mechanistic paradigms of
nuclear receptor action and identiﬁed vast gene networks governed
by individual nuclear receptors [1]. When functional genomics studies
are integrated with comprehensive experimental validation in cell-
based and animal models subjected to genetic, pharmacological, andphysiological perturbations, it becomes possible to uncover novel
nuclear receptor-dependent biological functions (Fig. 1). This amal-
gamation of approaches, which we referred to herein as physiological
genomics, can directly link biological phenotypes to well-deﬁned
molecular mechanisms. Although this investigative method can be
applied to all nuclear receptors, it is perfectly suited for the study of
orphan nuclear receptors. In this review, we highlight the successful
use of this method that led to the identiﬁcation of biological functions
inﬂuenced by the three members of the estrogen-related receptor
(ERR, NR3B) subfamily of orphan nuclear receptors in both normal
physiology and in disease state.
2. A brief initiation to the ERRs
Since several recent reviews have described in details the origin,
biological, and functional properties of the ERRs [2–5], only salient
features of these receptors related to the subject of this review will be
presented herein.
The ERR subfamily includes three members referred to as ERRα
(NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3). ERRα was originally
cloned during a search for newmembers of the superfamily of nuclear
receptors using a complementary cDNA encoding the estrogen re-
ceptor α (ERα, NR3A1) [6]. However, ligand binding studies and
transient transfection experiments with reporter genes failed to link
natural estrogens to, or to identify another class of natural signalling
molecules for this new receptor. ERRα was therefore classiﬁed as the
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Indeed, this attribute was reserved for ERRγ whose existence was
uncovered only a decade later [8]. In contrast, ERRβ was identiﬁed
shortly after ERRα using its cDNA as a probe [6]. But due in part to
its low level of expression in most tissues and to the early lethality of
the Esrrb knock-out mouse [9], ERRβ was not as intensively inves-
tigated as its nearest relative, ERRα. In view of the close structural
relationship between ERRα and ERα, initial studies on ERRα focused
on possible functional interactions between ERRα and ERα in
estrogen-responsive tissues and cancer cells, including the sharing
of coregulatory proteins and DNA-binding elements [2,10,11]. Al-
though several synthetic drugs, including many estrogenic com-
pounds such as diethylstilbestrol and 4-hydroxytamoxifen, have been
shown to inﬂuence the transcriptional activity of the ERRs [12–20],
all three ERR isoforms are still considered bona ﬁde orphan nuclear
receptors.
Like other members of the nuclear receptor superfamily, the ERRs
regulate gene expression through binding to a speciﬁc sequence in the
regulatory regions of target genes. The binding site for the ERRs,
referred to as an ERRE, was deﬁned as TNAAGGTCA using an unbiased
binding site selection approach [21]. The transcriptional activity of the
ERRs is constitutive and independent of exogenously added ligands.Fig. 1. Physiological genomics of nuclear receptors. Schematic representation of the compon
organ, or the whole organism, top) is perturbed using methods such as gene knock-out or
system is then analyzed for alterations in gene expression (DNAmicroarrays) and occupancy
phenotypic changes in the system (left). Information obtained via these two parallel invest
system. After one ormore reiteration of this cycle, novel biological functions associated with a
a process that can also lead to the development of novel therapeutic applications (bottom)However, the activity of the ERRs is highly dependent on the presence
of coactivator proteins, most notably that of peroxisome proliferator-
activated receptor γ (PPARγ)-coactivator 1 α (PGC-1α) and PGC-1β
[22–29]. The ERRs can also interact with and be stimulated by
members of the steroid receptor coactivator (SRC) family [30–33]. On
the other hand, the transcriptional activity of the ERRs can be potently
suppressed by the orphan nuclear receptor small heterodimer part-
ner (SHP, NR0B2) [34], the nuclear receptor interacting protein 140
(RIP140, NRIP1) [32,35–37] and the homeodomain-containing pro-
tein PROX1 [38]. Therefore, the relative levels of speciﬁc coactivator
and corepressor proteins present in a given cell type likely dictate
whether the ERRs act as activators or repressors of gene expression in
a given tissue or cell line.
One or more ERR isoforms are expressed in each cell or tissue
investigated to date [39]. In particular, the three ERR isoforms are
expressed at high levels in the heart and kidneys, two tissues with
elevated energy demand. The expression of ERRα is ubiquitous but can
be observed at higher levels in the intestine, brown fat, skeletalmuscle,
and cytokine-activated macrophages [6,21,40]. The distribution of
ERRβ is more limited, but substantial levels of expression have been
reported in the eye, inner ear, and the extra-embryonic ectoderm of
the developing placenta, aswell as inmouse but not human embryonicents of a physiological genomics analysis. A biological system (cells in culture, a speciﬁc
knock-down, overexpression, and/or pharmacological or physiological challenges. The
(ChIP-chip or ChIP-seq) proﬁles and to build regulatory networks (right), as well as for
igative paths are then integrated and used to design more speciﬁc perturbations in the
particular nuclear receptor can be uncovered (e.g., mitochondrial biogenesis for ERRα),
.
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developing heart, the brain stem, and the spinal cord [39,45]. Of note,
the expression of the three ERR isoforms has been shown to display
diurnal rhythmicity in several tissues that include the liver, skeletal
muscle, white fat, kidneys, bones, and uterus [46–48].
3. Functional genomics of nuclear receptors at a glance
3.1. Gene expression analysis
The most common approach to assess the contributions of a
nuclear receptor to the gene expression proﬁle in a system is achieved
using perturbation assays followed by measurement of variations in
mRNA levels of the target genes [49]. Gene expression proﬁles can
subsequently be submitted to various functional and bioinformatic
analyses to cluster the transcripts according to their expression
pattern and to extract informations about gene ontology and various
known biological pathways that are affected by the perturbation.
A convenient approach to perturb the activity of nuclear receptors
in the system prior to measurement of RNA transcripts of target
genes consists in using speciﬁc ligands to modulate the activity of
the receptor. For example, several studies have treated estrogen-
responsive cells with estradiol and selective estrogen receptor modu-
lators in order to identify target genes affected by various ERα ligands
in different contexts [50–52]. There are at least two well-known
caveats to these pharmacological studies. First, even with the best-
characterized compounds, there is always a possibility that the drug
affects, directly or indirectly, other factors and signalling pathways
within the cell. Second, this approach cannot easily differentiate be-
tween primary and secondary targets of the receptor. Given the rarity
of ERR-speciﬁc ligands, this approach has not been very helpful to
study ERR function to date. However, a recent study using a newly
identiﬁed inverse agonist for ERRα (Compound A) has shown that the
expression of ERR validated metabolic target genes can be modulated
by pharmacological agents [53]. Therefore, such an approach should
contribute in the near future to elucidate ERR-dependent pathways
in cell- and mouse-based models.
Since a ligand-based approach has not yet materialized to analyze
ERR-dependent changes in transcriptomes, alternative methods to
stimulate the activity of these orphan receptors have been developed.
For instance, overexpression of the coactivator PGC-1α or of a variant
of the coactivator that speciﬁcally interacts with ERRα has been used
to modulate the activity of the receptor [29,54–56]. Overexpression
of ERRα itself in cells expressing PGC-1α and PGC-1β has also been
used to identify potential ERRα target genes [57]. Conversely,
methods that consist in deleting (gene knock-out) or partially
depleting the receptor (gene knock-down) in the system have been
employed to identify biological pathways modulated by the ERRs
[45,48,56,58–60].
3.2. Integrative genomics
As mentioned above, while useful to gain insights on the action
of speciﬁc ligands or perturbation in different cell contexts, the
identiﬁcation of gene expression proﬁles does not necessarily
distinguish between primary and secondary targets of the nuclear
receptor being modulated. The initial attempts in identifying nuclear
receptor direct target genes were based on reverse functional geno-
mics consisting in inspection of promoters of responsive genes to
detect nuclear receptors binding sites, a low-throughput and in-
efﬁcient process. In the case of ERRα, this was achieved initially
through the identiﬁcation of the ERRα-binding site by unbiased
binding site selection, manual inspection of the promoters of ERRα-
responsive genes, and/or functional analyses of promoter regions
[21,56,58,61–64]. One of the ﬁrst global approach that identiﬁed a
signiﬁcant number of potential ERR direct target genes consisted inthe development of large-scale integrative genomics where the
promoters of differentially expressed genes modulated upon over-
expression of PGC-1α in mouse myoblast cells were analyzed for
de novo motif discovery [29]. This approach indeed showed an
enrichment for ERRE-like sequences in the promoters of these genes.
3.3. Location analysis
Over the last few years, improvement of the ChIP technique [65,66]
and development of large-scale genomic technologies such as ChIP-
on-chip [67] and ChIP-Seq [68] have allowed global scale location
analyses of transcription factors, co-factors, and RNA-polymerase II,
as well as histone modiﬁcation marks in various cellular contexts.
Integration of various location analyses in a speciﬁc system further
puts in relation the binding of nuclear receptors throughout the
genomewith active or repressed promoters and enhancers delineated
by speciﬁc epigenomic marks and RNA-PolII recruitment [69]. The
development of more advanced techniques like ChIA-PET further
allows linkage of distinct genomic regions that together cooperate
in gene regulation [70]. Therefore, the identiﬁcation of functional
nuclear receptor binding sites throughout the genome has the
potential to provide a more comprehensive and mechanistic view of
the transcriptional networks that it directly regulates.
Numerous studies using location analyses approaches have ex-
tensively contributed to the discovery of functional nuclear receptor
binding sites and networks in various contexts, especially for liganded
receptors like ERα [1]. An important observation emerging from these
studies is that some nuclear receptors like ERα are preferentially
recruited to distal regions from gene promoters [71]. However,
chromosome- and genome-wide ERRα [72] and ERRβ [73] location
analyses have shown that the proportion of ERR-binding sites located
within promoter regions of target genes is signiﬁcantly higher than for
ERα. Detection of transcription factor-binding sites at the genomic
scale also allows identiﬁcation of DNA response elements using
bioinformatics tools. The study of the DNA sequences bound by ERRα
obtained by ChIP-on-chip in human breast cancer cells has univocally
dissociated ERRα recruitment from that of ERα at the genomic level
[74]. While both classes of receptors can recognize ERα-binding sites
(EREs) and compete for occupancy to these sites in vitro [33,75,76], de
novo binding site discovery on ERRα ChIP-on-chip target sequences
revealed that in an in vivo context, ERRα speciﬁcally binds to ERREs
and only competes with ERα on EREs that also contain an embedded
ERRE. Future functional genomics studies are thus likely to reveal
additional mechanisms that will distinguish between the molecular
mode of action of the ERRs from other nuclear receptors.
3.4. Building transcriptional networks
Examination of DNA response elements present in the vicinity
of the nuclear receptor binding sites can also reveal functional
association between different types of transcription factors. For
example, analyses of ERα-bound sequences in MCF-7 cells coupled
with extensive experimental validation, identiﬁed FOXA1 as a
licensing factor for ERα-regulated transcriptional activity in breast
cancer cells [77,78]. The initial location analyses studies for ERRα in
various tissues also revealed enrichment of binding sites for other
transcription factors like STAT3, CREBP, and NRF1 in the vicinity of
ERRα bound segments, indicating that these factors might cooperate
with ERRα in the transcriptional regulation of a large subset of genes
[38,60,72]. Examination of the DNA sequences surrounding nuclear
receptor binding sites can also be used to deﬁne functional tran-
scription regulatory modules that are informative on the mode of
action of the receptor [79]. In addition, chromosome-wide and ex-
tended promoter regions location analyses of the ERRα coactivator
PGC-1β have shown a strong overlap with ERRα-bound regions in
breast cancer cells [72]. Bioinformatic studies have identiﬁed the
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that PGC-1β is the preferential coactivator for ERRα in these cells.
4. A physiological genomic view of ERR-driven
biological functions
Functional genomic techniques are now being used to uncover
large-scale interconnections between gene expression proﬁles,
nuclear receptor genomic recruitment, chromatin landscape, and
various signalling pathways that contribute and work in relation
with one another in establishing the genetic program of the cell. As
discussed in the next sections, integration of gene expression proﬁles,
location analyses data, and phenotypic analyses of ERR-perturbed
biological systems have been used to uncover several functions of the
ERRs in normal physiology and in the disease state. A summary of
these ﬁndings is presented in Table 1.
4.1. ERRs as global regulators of mitochondrial biogenesis and energy
metabolism
The initial characterization of the gene encoding medium-chain
acyl coenzyme A dehydrogenase (MCAD or ACADM), a protein that
mediates the initial step in mitochondrial β-oxidation of fatty acids, as
the ﬁrst bona ﬁde ERRα target led to the suggestion that ERRα might
play an important role in regulating cellular energy balance [21,62].
This ﬁnding was later corroborated by the discovery that ERRα and
ERRγ interact with and are activated by PGC-1α and PGC-1β, two
coactivators known for their crucial role in regulating energy
metabolism [80]. Indeed, overexpression of PGC-1α or of functionally
adapted variants of the protein, as well as of ERRα itself demonstrated
an unambiguous link between ERRα, PGC-1α and changes in the
expression of genes speciﬁcally involved in the control of cellular
energy metabolism [29,54,56,57]. Additional studies using various
strategies described above also established that one or more ERR
isoforms control the expression of genes involved in lipid transport
and uptake [58], mitochondrial biogenesis and function [81–83], asTable 1
Physiological genomics analyses of ERR biological function.
Methods Biological system Biologica
Expression proﬁling/integrative genomics C2C12 cells expressing PGC-1α ERRα par
Expression proﬁling MCF-7 and BT-474 cells treated
with an ERRα antagonist
Energy m
Expression proﬁling HepG2 cells expressing an
ERRα-speciﬁc PGC-1α mutant
Energy m
lipid met
Expression proﬁling MCF-7 cells expressing cells an
ERRα-speciﬁc PGC-1α mutant
Aerobic m
Expression proﬁling SAOS2 cells expressing PGC-1α Mitochon
Expression proﬁling Primary neonatal cardiac
myocytes expressing ERRα
Mitochon
Expression proﬁling Intestine of ERRα-null mice OXPHOS,
and abso
Expression proﬁling Renal, gastric, and cardiac tissues
in perinatal ERRγ-null mice
Ion trans
Expression proﬁling/ChIP-on-chip ERRα-null mouse macrophages/
macrophages, ERRα Abs
ROS prod
ChIP-on-chip Mouse liver, ERRα Abs Energy m
Expression proﬁling/ChIP-on-chip ERRγ-null mice hearts/fetal hearts,
ERRγ Abs
Energy ge
Expression proﬁling/ChIP-on-chip ERRα-null mice kidneys/kidney,
ERRα Abs
Renal Na+
renin-ang
Expression proﬁling/ChIP-on-chip ERRα-null mice hearts/adults hearts,
ERRα and γ Abs
Energy ge
ChIP-on-chip SKBr3 cells Gene exp
ChIP-seq Mouse ES cells, ERR pan-Abs Self-renew
in ES cells
ChIP-on-chip MCF-7 and SKBr3 cells, ERRα Abs Cell grow
producing
Abs: antibodies; ES, embryonic stem; N/A, not applicable; OXPHOS, oxidative phosphorylatwell as in oxidative phosphorylation and in the tricarboxylic acid
(TCA) cycle [25,45,60,84]. However, the deﬁnitive validation that the
ERRs directly regulate these metabolic gene networks was provided
by a series of genome-wide ChIP-on-chip and ChIP-seq studies
[25,38,45,48,60,73,74]. Through this work, signiﬁcant enrichment of
one or more ERR isoforms was detected at regulatory regions of
most metabolic genes identiﬁed previously via gene expression
studies, and bioinformatic analyses conﬁrmed that the ERRs interact
with genomic DNA almost exclusively through the well-deﬁned ERRE.
Remarkably, ERRα was found to occupy the promoter regions of
practically all genes encoding enzymes participating at every step in
the glycolytic pathway, pyruvate metabolism, and TCA cycle [38] in
liver tissue. Collectively, the ERRs have been shown to occupy the
promoter region of more than 700 genes encoding mitochondrial
proteins (Table 1). In addition, these studies have also highlighted a
global role for the ERRs in regulating gene networks implicated in
growth factor/insulin signalling, energy sensing, translation, and the
glucosamine pathway (Fig. 2).
Does a correlation exist between the ERR-dependent metabolic
gene regulatory networks uncovered by functional genomics and the
roles played by the three receptors in the whole organism? At ﬁrst
glance, the initial phenotypic observation that the ERRα-null mice are
lean and resistant to high-fat diet-induced obesity does not appear to
harmonize very well with a predominant function for ERRα and ERRγ
in up-regulating genes involved in mitochondrial oxidative metabo-
lism [85]. However, more in-depth investigations of the ERRα- and
ERRγ-null mice revealed a much better than anticipated coordination
between the functional genomics data and the phenotypic responses
of these mice to diverse physiological challenges.
First, ablation of the ERRα gene in mice accelerates the bioenergetic
and functional signatures of heart failure in the context of pressure
overload [86]. Indeed, ERRα-null mice subjected to left ventricular
pressure overload displayed signatures of heart failure including
chamber dilatation, abnormal phosphocreatine depletion, and
reduced maximal ATP synthesis rates in the heart. In addition,
ERRα target genes involved in energy substrate oxidation, ATPl function Related disease Ref
tners with PGC-1α Diabetes Mootha et al. [29]
etabolism and OXPHOS Breast cancer Chisamore et al. [53]
etabolism and OXPHOS,
abolism and transport
N/A Gaillard et al. [54]
etabolism and tumor biology Breast cancer Stein et al. [55]
drial biogenesis Diabetes Schreiber et al. [56]
drial energy producing pathways Diabetes and heart failure Huss et al. [57]
dietary lipid digestion
rption
Intestinal function Carrier et al. [58]
port, hypertension Renal, gastric and cardiac
dysfunctions
Alaynick et al. [59]
uction Infectious diseases Sonoda et al. [25]
etabolism and OXPHOS Diabetes Charest-Marcotte
et al. [38]
neration, sensing and utilization Cardiac hypertrophy Alaynick et al. [45]
/K+ handling, blood pressure,
iotensin pathway
Bartter syndrome and
hypertension
Tremblay et al. [48]
neration, sensing and utilization Cardiomyopathies Dufour et al. [60]
ression in the ERBB2 amplicon Breast cancer Deblois et al. [72]
al, pluripotency, reprogramming Stem cell-based therapy Chen et al. [73]
th, signalling and cellular energy
pathways
Breast cancer Deblois et al. [74]
ion; Ref, reference.
Fig. 2. Physiological targets of ERR involved in energy homeostasis. ERRα regulates target genes involved in growth factors/insulin signalling (orange), energy sensing (magenta),
translation (green), glucosamine pathway (blue), transcription (red), and energy generating apparatus (TCA cycle, OXPHOS, and glycolysis, yellow).
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null hearts at baseline or with pressure overload. Collectively, the
gene expression results were consistent with the metabolic assess-
ment of ERRα-null hearts as altered expression of ERRα target genes
involved in fatty acid oxidation, TCA cycle, oxidative phosphoryla-
tion, and the synthesis and translocation of ATP complex were
observed in the hypertrophied hearts. In addition, the ERRα-null
hearts exhibited a reduction in the expression of two AMP kinase
subunits, Prkab1 and Prkab2, which is accompanied by reduced AMP
kinase and acetyl-CoA carboxylase α (ACC1) phosphorylation [60],
as well as by abnormal expression of genes involved in high-energy
phosphate transfer such as Ckmt1 and Ant1. Thus, this work not only
validated the functional genomic analyses of ERRα as a transcription
factor but also identiﬁed ERRα as a crucial determinant for the
functional adaptation of the heart to hemodynamic stress forced by
pressure overload.
Second, disruption of the gene encoding ERRγwas shown to block
the metabolic switch that occurs at birth in the heart from a prevalent
dependence on carbohydrates during fetal life to a greater reliance on
postnatal oxidative metabolism in the newborn heart [45]. Interest-
ingly, these studies showed that while ERRα and ERRγ target the
same metabolic gene networks, the two receptors exert distinct
functions in the control of energymetabolism in the same tissue in the
life-long context of the whole organism.
Third, ERRα-deﬁcient mice exposed to a moderately cold envi-
ronment are unable to maintain their core body temperature due to a
defect in adaptive thermogenesis [84]. While ERRα does not appear to
be required for the induction of thermogenic genes in brown adipose
tissues, the absence of ERRα correlates once again with a reduction in
mitochondrial biogenesis and oxidative capacity required to provide
the energy necessary to generate heat.Fourth, ERRα and its coactivator PGC-1β were shown to regulate
mitochondrial output in macrophages activated by interferon γ (IFN-
γ) [25]. The deﬁciency inmitochondrial function in thesemice led to a
decrease in intracellular reactive oxygen species (ROS) level and
clearance of Listeria monocytogenes in IFN-γ-activated macrophages.
This phenotype correlated with the ﬁndings that ERRα and PGC-1β
are both required for the induction of ERRα target genes encoding
components of the mitochondrial respiratory chain machinery.
Taken together, these studies demonstrated that while ERRα
appears to be dispensable for basal cellular energy needs, its presence
is deﬁnitively required to provide the levels of energy necessary to
respond to physiological and pathological insults in diverse tissues.
In contrast, ERRγ is essential to establish and maintain the basal
oxidative metabolic gene program in the heart. Similarly, disruption
of ERRγ activity in human breast cancer and mouse mammary tumor
cells via the expression of a micro RNA (miR-378*) also promotes a
metabolic shift, known as the Warburg effect, characterized by a
reduction in TCA cycle gene expression and oxygen consumption, as
well as an increase in lactate production [87].
4.2. ERRα and ERRγ as regulators of ions homeostasis
The kidneys regulate blood pressure via the production of renin,
the rate-limiting step of the renin–angiotensin pathway, and the
maintenance of electrolyte homeostasis. Using a physiological
genomics approach directed at the kidneys, we recently demonstrated
that ERRα is located at the promoter and controls the expression of
genes encoding channels involved in Na+ and K+ handling, the renin–
angiotensin pathway, and several genes encoding systemic regulators
of blood pressure [48]. Physiological analysis of ERRα-null mice
corroborated these ﬁndings as the knock-out mice, relative to their
Fig. 3. The ERRs modulate breast cancer cells bioenergetics. ERBB2 signalling modulates
the expression of PGC-1β and the activity of ERRα in ERBB2-positive breast cancer cells.
PGC-1β contributes to the activity of ERRα in regulating the expression of genes
involved in cell growth and proliferation as well as in glycolysis in breast cancer cells
(right panel). ERRγ promotes the expression of OXPHOS genes in breast cancer cells
(left panel). The PGC-1β gene also encodes for miR-378, a micro-RNA that targets ERRγ
and contributes to mediate the metabolic shift towards a glycolytic phenotype that
prevails in breast cancer cells.
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mice display a deﬁciency in Na+ and K+ handling with a mechanism
supporting Na+ retention. ERRα is required to sustain elevated blood
pressure during the period of nocturnal activity of the mice.Fig. 4. A physiological response pathway with ERRα, β and γ as its focal point. External stimu
target tissue. Interpretation of the signal leads to the induction of the transcriptional activity
the modulation in the expression of vast gene networks. The resulting signal output dictateIn keeping with the theme that ERRα and ERRγ target the same
metabolic gene networks but perform distinct physiological functions,
ERRγ has been shown to be a regulator of genes central to ion
homeostasis in renal, gastric, and cardiac tissues [59]. While ERRα-
null mice display a relatively mild renal phenotype, ERRγ-null mice
die shortly after birth with elevated serum K+, a reduction of markers
of gastric acid production and cardiac arrhythmia.
4.3. ERRβ is a reprogramming factor in stem cell biology
Pluripotent stem cells have the ability to give rise to cell types of
all three germ layers as well as the germ line. Embryonic stem cells
can also proliferate in an unlimited manner while maintaining their
pluripotent state. Recently, genetic reprogramming has been used to
induce pluripotency and self-renewal in mature cell types such as
ﬁbroblasts [88]. Several factors and extracellular signalling molecules,
working in various combinations, have been shown to be able to
reprogram the cellular phenotype of differentiated cells [89]. One
of these factor is ERRβ [90]. ERRβ can reprogram mouse ﬁbroblasts
when introduced in combination with POU5F1 and SOX2 and can
substitute for KLF4, one of the four original reprogramming factors.
Interestingly, genome-wide location analysis has shown that sites
enriched for ERRβ binding also contain binding sites for KLF family
members [73]. In addition, ~60% of ERRβ-binding sites within mul-
tiple transcription factor-binding loci (MTL) were found in NANOG/
OCT4/SOX2MTL. However, phenotypic analysis of ERRβ-null mice has
shown that knock-out embryos die at mid-gestation with placentalli such as exercise and feeding/fasting serve as input signals that elicit a response from a
of one or more members of the ERR subfamily of nuclear receptors, which then results in
s a ﬁtting cell-speciﬁc biological response.
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reprogramming of mouse ﬁbroblasts, it is likely that genetic redun-
dancy, as previously observed for the three ERRs in other tissues
[48,59,60], prevents the observation of a strict requirement for ERRβ
in the embryonic lineage. It should be noted that the antibody used to
detect ERRβ binding sites in the mouse embryonic stem cells study
also recognizes ERRγ [73].
4.4. ERRα as a determinant of breast cancer etiology
Since ERRα shares both structural and functional features with
ERα, it was originally suggested that it could contribute to the biology
of breast cancer. Initial studies have shown that the expression of
ERRα in breast tumors associates with negative prognosis and posi-
tively and inversely correlates with ERBB2 and ERα status, respec-
tively [91,92]. Moreover, the transcriptional activity of ERRα is
modulated by the EGF/ERBB2 signalling pathways in breast cancer
cells [93,94].
Depletion of ERRα in the ERα-negative cells MDA-MB-231 leads to
a reduction of the migratory potential of the cells and decreases the
tumor growth rate of xenografts [55]. Gene expression proﬁle of MCF-
7 cells stably expressing the ERRα-speciﬁc variant of PGC-1α revealed
that many affected genes play a role in metabolism. ERRα antagonists
inhibit tumor growth of both ERα-positive MCF-7 and ERα-negative
T47D cells in mouse xenograft [53]. Location analyses in breast cancer
cells revealed that the overlap between ERRα and ERα recruitment on
extended promoter regions of target genes was much lower than
initially expected, suggesting that ERRα also has an ERα-independent
function in breast cancer [74]. Both receptors display strict binding
site speciﬁcity and maintain independent mechanisms of transcrip-
tional activation. Nonetheless, ERRα and ERα co-regulate a small
subset of common target genes, many of which have been implicated
in the etiology of breast cancer. By intersecting ERRα target genes
identiﬁed using ChIP-on-chip in breast cancer cells with the gene
expression proﬁles of several cohorts of human breast tumors, it was
shown that ERRα signalling is involved in all the established breast
tumor subtypes and therefore contributes to the heterogeneity of the
disease [74].
ERRα and PGC-1β were shown to be recruited to the 17q12
chromosomal region of breast cancer cells and regulate the expression
of ERBB2 and of several co-ampliﬁed genes [72]. ERRα and ERα
display antagonist activity on the regulation of the ERBB2 gene. The
presence of ERRα is required for full tumor development in a mouse
model of Neu-initiated mammary tumorigenesis, and tumors lacking
ERRα express lower levels of several transcripts of the amplicon.
In contrast, ERRγ is inversely correlated to ERRα expression in
breast tumors and is a good prognosis factor [91]. As mentioned
above, it was shown that the mir-378*, which is encoded in the PGC-
1β gene, is modulated through ERBB2 signalling and targets ERRγ
expression in breast cancer cells, contributing to the metabolic shift
called theWarburg effect [87]. A schematic representation of the roles
played by each ERR and PGC-1 isoform in the regulation of cellular
energy metabolism in ErbB2-positive breast cancer cells is shown in
Fig. 3.
5. Conclusions and perspectives
Despite their relatively high cost and the lack of consensus analysis
methods, the advent of high throughput functional genomic techni-
ques for gene expression proﬁling and location analyses has trans-
formed the ﬁeld of nuclear receptor studies. These state-of-the-art
techniques are now being used to uncover large-scale interconnec-
tions between gene expression proﬁles, recruitment of nuclear
receptors to speciﬁc sites in genomes, chromatin landscape, and
various signalling pathways that work in relation with one another to
establish the genetic programs that contribute to the normal functionof the cell or underlying various pathologies. Herein, we have shown
that physiological genomics analyses led to the identiﬁcation of an
extensive physiological response pathway that has the ERRs as its
focal (Fig. 4). Increasingly, functional/physiological genomics studies
will direct future research towards the discovery of novel nuclear
receptor-driven biological functions, and hopefully, the development
of new therapeutic avenues targeting nuclear receptors for the
prevention and treatment of metabolic diseases and hormone-
dependent cancers.
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